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Natriuresis associated with elevated plasma 
atrial natriuretic hormone during 
supraventricular tachycardia 
Elevated plasma levels of atria1 natriuretic hormone (ANH) have been found In patients during 
paroxysmal supraventrlcular tachycardia (SVT) and other clinical syndromes. However, 
physiokglc effects of this endogenous ANH have not been demonstrated. To determine whether 
the rise In ANH during SVT is associated with either a natrluresls or kalluresis, urine sodium and 
potassium levels were measured in five patients at baseline and dutlng SVT simulated by rapid 
atrloventricular pacing. Plasma ANH levels increased from 149 -t 35 pmol/L at baseline to 
187 2 31 pmol/L (p = 0.007) during SVT. Plasma vasopressln and renln levels were unchanged. 
Urine sodium levels Increased 49% from 1.54 ? 0.66 mEq/hr at basellne to 2.29 + 0.89 mEq/hr 
(p = 0.044) during SVT, and urine potassium levels Increased 22% from 4.14 + 0.10 mEq/hr to 
5.04 2 1.25 mEq/hr (p = 0.018). Urine sodium and potassium levels returned to baseline values 
1 hour after pacing. Thus elevated plasma levels of ANH during SVT are associated wlth both a 
natrluresis and kalluresis, which may represent physiologic effects of the endogenously secreted 
hormone. (AM HEART J 1989;117:377.) 
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Vasoactive peptides termed atrial natriuretic hor- 
mone (ANH) have been isolated from animal and 
human atria1 tissue, sequenced, and synthesixed.*-5 
Infusion of ANH into animals has been demon- 
strated to produce an increase in urine, sodium, 
potassium, and chloride excretion; an increase in 
glomerular filtration rate and urine flow; an inhibi- 
tion of aldosterone secretion; a relaxation of vascular 
smooth muscle; and a systemic hypotensive effect.‘js 
Infusion of synthetic ANH into normal human 
volunteers has also produced significant natriuresis, 
kaliuresis, and diuresis.g* lo 
However, elevated plasma levels of endogenous 
ANH in patients are not generally associated with 
high urinary sodium or potassium excretion. 
Patients with congestive heart failure, chronic 
mitral stenosis, car puhnonale, or chronic renal 
failure with fluid overload have high levels of ANH 
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but frequently retain sodium rather than excrete it 
into the urine.“-I7 Although the absence of a natri- 
uresis or kaliuresis in these patients may be a result 
of other pathologic changes associated with their 
disease, the persistent sodium retention suggests 
that the elevated ANH levels may not have a 
physiologic effect. Therefore, this study was 
designed to determine whether transient rises in 
endogenous ANH are associated with a significant 
natriuresis or kaliuresis. Patients were chosen for 
study during supraventricular tachycardia (SVT) 
because previous investigations have demonstrated 
that this arrhythmia can be accompanied by large 
(lo-fold) increases in plasma ANH.l’ 
METHODS 
Patients were studied during SVT simulated by rapid 
simultaneous pacing of the atrium and ventricle. All 
subjects had undergone coronary artery bypass operations 
2 days before initial study, and atrial and ventricular 
pacing wires, central venous pressure lines, and indwelling 
Foley catheters were positioned for the study. Medica- 
tions were discontinued 12 hours before study except in 
one patient who received a constant intravenous infusion 
of dobutamine 10 Ilg/kg/min throughout the observation 
period. Informed written consent was obtained in accord 
with the University of Michigan Hospital guidelines. 
Fifteen-minute urine samples were collected for at least 
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Fia. 1. Urinarv volume. sodium, and notassium excretion during baseline and during and for 1 hour after 
simulated SVT: 
2 hours before pacing, during SVT, and for 2 hours after 
pacing. All patients were considered to have reached a 
stable baseline urine output defined as three successive 
collections varying by 11 ml. SVT was then simulated by 
rapid simultaneous atrioventricular pacing for 15 minutes. 
Pacing was begun at 140 bpm and increased to 150 bpm 
after 30 seconds unless discomfort or hypotension devel- 
oped. One patient experienced nonspecific discomfort at 
150 bpm and his rate was reduced to 140 bpm. Urine 
volume, osmolality, and sodium and potassium concentra- 
tions were measured in all collections except in one 
patient who received an intravenous diuretic during the 
final study hour. Subsequent urine collections in that 
patient were discarded. Electrolyte concentrations were 
determined with a Beckman Astra analyzer (Beckman 
Instruments Inc., San Diego, Calif.) with ion selective 
electrodes. Urine osmolality was determined with a Preci- 
sion Systems model 5004 osmometer (Precision Systems, 
Inc., Sudbury, Mass.). 
Arterial blood samples for measurement of ANH, vaso- 
pressin, and renin were obtained at baseline immediately 
before pacing, at the end of pacing, and 30 minutes after 
termination of pacing. Central venous pressure and arteri- 
al pressure were recorded just before each arterial sam- 
pling. All blood samples for ANH were collected in tubes 
containing ethylenediamine tetraacetic acid, placed on ice, 
and centrifuged. The plasma samples were stored at 
-70°C and extracted with the use of Cl8 octadecylsilane 
cartridges (Sep-Pak, Waters Associates, Milford, Mass.). 
The radioimmunoassay was performed with the use of an 
antibody against 1-28 a-human atrial natriuretic polypep- 
tide purchased from Peninsula Laboratories Inc. (Bel- 
mont, Calif.). Synthetic atriopeptin III was iodinated with 
chloramine-T and separated by high-performance liquid 
chromatography. Monoiodinated peptide was used as a 
trace. The complete procedure has been previously 
described.12 Vasopressin and renin levels were also mea- 
sured by standard radioimmunoassays. 
SVT was initiated in eight patients. No one had angina 
or dyspnea during pacing.18 However, in three patients the 
mean arterial pressure fell by more than 10 mm Hg at a 
rate of 140 bpm, and these patients were excluded from 
further study. The remaining five patients constituted the 
study group. The average age was 57 years (range 48 to 70) 
and all were men. None had had a previous myocardial 
infarction and each had a preoperative left ventricular 
ejection fraction >50%. There was no history of renal 
dysfunction in any patient defined as a serum creatinine 
level >1.5 mg/dl or previous proteinuria. 
Urinary sodium and potassium excretion were 
expressed as milliequivalents per unit of time. Urine 
osmolality for periods >15 minutes was calculated from 
the total osmoles per volume. Group differences between 
patients at baseline and during SVT were compared by a 
paired t test. Single and multivariate linear regression 
analyses were used to examine relationships between 
variables. All group values are expressed as the mean + 
standard error of the mean. 
RESULTS 
Plasma levels of ANH increased 26% (p = 0.0966) 
during SVT and returned to baseline levels within 
30 minutes after pacing (Table I). Levels of vaso- 
pressin and renin did not change significantly dur- 
ing or after SVT. The baseline plasma level of ANH 
was significantly elevated compared with that of 
normal volunteers as measured in this labora- 
ory (149 rf: 35 pmol/L versus 18 + 2 pmol/L, 
p = 0.001). 
Baseline central venous pressure was 10 f 2 mm 
Hg, increased to 12 it_ 3 mm Hg during SVT, and fell 
to 11 rfr 2 mm Hg after pacing. These changes in 
pressure were not significant. In addition, there was 
no relationship between the changes in central 
venous pressure and plasma ANH, vasopressin, or 
renin levels. Arterial pressure was not significantly 
different before (87 + 4 mm Hg), during (89 f 5 
mm Hg), or after (90 t- 5 mm Hg) SVT. 
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149 -t_ 25 6.0 + 3.0 
187 * 31* 8.1 f 4.3 
133 + 21 5.8 -+ 2.6 
Renin 
(w/L) 
10.8 f 4.5 
8.1 k 3.6 
8.3 dz 3.9 
‘p = 0.007 veraus baseline value. 
All patients showed an increase in urine sodium 
and potassium excretion. The onset of the change in 
urine electrolytes began during SVT in four patients 
and during the 15 minutes after pacing in one 
patient. Increased excretion lasted for 45 minutes in 
one patient and for at least 1 hour in the other four 
patients. Urine sodium levels increased 49% from 
1.54 + 0.66 mEq/hr at baseline to 2.29 f 0.89 mEq/ 
hr during SVT and for the hour after SVT 
01 = 0.044) (Fig. 1). Urine potassium levels in- 
creased 22% from 4.14 + 0.10 mEq/hr at baseline to 
5.04 f 1.25 mEqkr during and after pacing 
(p = 0.018). Urine volume showed a small, statisti- 
cally insignificant increase from 42 + 5 ml/hr at 
baseline to 54 + 9 ml/hr during and after SVT. 
Urine osmolality also rose insignificantly from 
707 + 60 mOsm/L to 734 + 44 mOsm/L b = ns). 
Serial urine collections during the second hour after 
SVT demonstrated a return to basal urine electro- 
lyte excretion (Fig. 2). Regression analysis showed 
no linear relationship between the increase in plas- 
ma ANH and the change in urine electrolytes 
expressed either as absolute increments or fractional 
changes. The addition of other variables including 
vasopressin and renin did not provide any additional 
correlation. There was also no correlation between 
changes in urine volume and osmolality with levels 
of ANH, vasopressin, or renin. 
DISCUSSION 
This study demonstrates that a small rise in 
plasma ANH levels can be associated with a signifi- 
cant natriuresis and kaliuresis. Plasma ANH levels 
increased only 38 f 7 pmol/L, a 26% increment 
from baseline levels, yet it was still accompanied by 
increases of 49 % and 22% in urinary sodium and 
potassium excretion, respectively. This suggests that 
endogenous ANH, detected by plasma radioimmu- 
noassay, is physiologically active. 
Vasopressin and renin did not change significantly 
during this study and do not appear to be related to 
the natriuresis associated with SVT.” However, the 
effects of minor neurohumoral changes (Table I) 
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Fig. 2. Serial changes in urine sodium excretion, urine 
potassium excretion, and plasma ANH levels in individual 
patients. Measurements were made before, during, and 
after simulated SVT. 
For example, the increase in vasopressin levels, 
although not statistically significant, may have con- 
tributed to the reduction in urine volume and 
increase in urine osmolality. The polyuric response 
typically associated with SVT includes an increase 
in urine flow, free water clearance, and a fall in urine 
osmolality, along with an increase in sodium excre- 
tion.1g-2* The absence of significant changes in urine 
volume, free water clearance, and urine osmolality 
may have been due to the elevated central venous 
pressures at baseline. These high pressures had 
probably already produced atrial distension and 
high plasma ANH levels .11-14, 22-25 Similarly, vasopres- 
sin may have been partially suppressed.25y26 The 
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small additional increment in central venous pres- 
sure led to smaller than expected increases in ANH 
and no significant change in vasopressin. In patients 
without elevated filling pressures, more dramatic 
changes in ANH, vasopressin, and urinary excretion 
could be anticipated. 
The natriuresis and kaliuresis in these patients 
lasted for approximately 1 hour despite the return of 
ANH to baseline levels within 30 minutes of the 
termination of SVT. Thus the physiologic effects of 
ANH appear to persist for 30 to 60 minutes after the 
original stimulus for secretion and increase in plas- 
ma ANH levels have disappeared. Bolus infusions of 
synthetic a-human atrial natriuretic polypeptide 
have also produced increases in urinary excretion of 
sodium that last longer than the elevation in mea- 
surable plasma leve1s.s Although an additional natri- 
uretic stimulus could be hypothesized, these obser- 
vations suggest that ANH alone could account for 
the increased electrolyte excretion during SVT. 
Other experimental data, however, suggest that 
ANH released as a result of atria1 distention is not 
the sole stimulus for natriuresis. Atria1 distention of 
a denervated heart in a conscious dog can produce 
significant rises in ANH without a detectable natri- 
uresis.27,2s Similarly, a natriuresis after infusions of 
ANH can be suppressed by decreasing renal perfu- 
sion pressure. 2g Whether cardiac innervation is 
required for secretion of an active form of ANH or 
whether an additional neurohumoral mechanism 
must be activated or suppressed to permit a natri- 
uresis is unclear. Nevertheless, the temporal rela- 
tionship of the increase in plasma ANH levels to the 
natriuresis and the known physiologic properties of 
ANH suggest that it plays an important role in the 
natriuresis associated with SVT. 
In conclusion, this study demonstrates that a 
small increase in plasma ANH can be associated 
with a significant natriuresis and kaliuresis. Thus 
endogenous ANH as measured by radioimmunoas- 
say appears to have physiologic activity. Further- 
more, the natriuresis associated with SVT appears 
to be modulated, at least in part by plasma levels of 
ANH. 
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Rapid fall in elevated plasma atrial natriuretic 
peptide levels after successful catheter balloon 
valvuloplasty of mitral stenosis 
To determine whether an acute fall in atrial pressure decreases the secretion of atrial natriuretic 
peptide in man, changes In the plasma levels of this peptide were studied after catheter balloon 
valvuloplasty of the mitral valve. Ten patients with severe mitral stenosis were included in the 
study. The valvuloplasty resulted in an immediate reduction in left atrial pressure and an increase 
in the mitral valve area. Decreases in right atrial pressure were inconsistent and less significant. 
Plasma atrial natriuretic peptide levels, which were elevated before the valvuloplasty, decreased 
significantly in all 10 patients at 15 minutes after the valvuloplasty and reached lower plateaus at 
30, 45, and 60 minutes after the procedure. In the seven patients studied for a longer period, 
both plasma atrial natriuretic peptide levels and the left atrial pressure remained reduced 24 
hours after the valvuloplasty. Plasma atrtal natriuretic peptide levels before and 30 to 60 minutes 
after the valvuloplasty were positively correlated to simultaneously determlned left and right 
atrial pressures. These results indicate that atrial stretch caused by increased atrial pressure is 
an important stimulus for atrial natriuretic peptlde release In man. “De-stretching” of the 
myocytes of the atria results in rapid inhibition of atrial natriuretlc peptlde secretion. (AM HEART J 
1989;117:381.) 
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It is established that atrial natriuretic peptide 
(ANP) with potent diuretic, natriuretic, vasodilata- 
tory, and aldosterone-inhibiting activities is se- 
creted from the myocytes of both atria. Plasma 
levels of ANP are elevated in patients with chronic 
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congestive heart failure with a concomitant increase 
in atrial pressures.1-3 This suggests that atrial stretch 
plays an important role in increasing ANP secretion 
in man, as has been evidenced in experimental 
animalsL6 Furthermore, our previous observation of 
a rapid rise in plasma ANP levels after induction of 
paroxysmal atrial tachycardia by electrical stimula- 
tion suggests that atrial myocytes respond rapidly to 
a rise in atrial pressure by secreting ANP.7 
The recent introduction of catheter balloon valvu- 
loplasty (CBV) for the treatment of mitral steno- 
sishg has provided a unique human model for the 
study of changes in ANP secretion before and after a 
reduction in atrial pressures. Waldman et aLlo 
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